# Supporting Information 

# Inhibiting HTLV-1 Protease: A Viable Antiviral Target 

Gordon J. Lockbaum ${ }^{1}$, Mina Henes ${ }^{1}$, Nathaniel Talledge ${ }^{2}$, Linah N. Rusere ${ }^{1}$, Klajdi Kosovrasti¹, Ellen A. Nalivaika ${ }^{1}$, Mohan Somasundaran ${ }^{1}$, Akbar Ali ${ }^{l}$, Louis M. Mansky ${ }^{2}$, Nese Kurt Yilmaz ${ }^{1}$, Celia A. Schiffer ${ }^{l}$
${ }^{1}$ Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, United States
${ }^{2}$ Institute for Molecular Virology, Masonic Cancer Center, University of Minnesota - Twin Cities, Minneapolis, Minnesota 55455, United States

## SUPPLEMENTARY FIGURES



Figure S1. Representative dose-response curves. Initial velocity $\left(\mathrm{V}_{\mathrm{i}}\right)$ as a function of inhibitor concentration was globally fit for 3 replicates (Rep 1-3) to obtain the inhibition constants $\left(\mathrm{K}_{\mathrm{i}}\right)$.


Figure S2: Immunoblot quantification of full-length (FL Gag) band as a percentage of total bands in each lane for the different $S P$ cell drug treatments reported as the mean $\pm \operatorname{SEM}(\mathrm{n}=3)$.


Figure S3: Per-residue vdW contacts between protease and inhibitor, grouped by inhibitor moiety.


Figure S4: Root-Mean-Square Fluctuation (RMSF) of Ca atoms for DRV, UM6 and PU6 in complex with HTLV-1 protease from molecular dynamics simulations. Ala59/59' residues are at the tips of the flaps in HTLV-1 protease (corresponding to Ile50/50' in HIV-1 protease), and Trp98/98' are at the P1/P1' subsites of the active site.


Figure S5. Aromatic side chains in HTLV-1 active site can form $\pi-\pi$ stacking interactions, primarily in edge-to-face configuration, with the P1 phenylalanine and P2' aniline of DRV analogs. Frequency of the $\pi-\pi$ stacking interactions (dashed lines) during MD simulations is indicated.

## SUPPLEMENTARY TABLES

Table S1. HIV-1 protease and HTLV-1 protease viral polyprotein cleavage sites.

| Cleavage Site | HIV-1 <br> (P4-P1/P1'-P4') | HTLV-1 <br> (P4-P1/P1'-P4') |
| :---: | :---: | :---: |
| MA/CA | SQNY/PIVQ | PQVL/PVMH |
| CA/NC | - | TKVL/VVQP |
| Gag/PR | SFNF/PQIT | ASIL/PVIP |
| PR/Pol | TLNF/PISP | PVIL/PIQA |
| Pro/RT | - | PAVL/GLEL |
| RT-RH/IN | RKIL/FLDG | VLQL/SPAD |

Table S2. Enzymatic activity of HTLV-1 protease measured using natural substrate sequences.

| Cleavage Site | Sequence <br> $\left(\mathbf{P 4}-\mathbf{P 1} / \mathbf{P 1} \mathbf{' P 4}^{\prime}\right)$ | $\mathbf{K}_{\mathbf{M}}(\boldsymbol{\mu} \mathbf{M})$ | $\mathbf{k}_{\text {cat }}\left(\mathbf{s}^{-1}\right)$ | $\mathbf{k}_{\text {cat }} / \mathbf{K}_{\mathbf{M}}\left(\boldsymbol{\mu}^{\mathbf{1}} \mathbf{M}^{-1} \mathbf{s}^{-1}\right)$ |
| :---: | :---: | :---: | :---: | :---: |
| $\mathbf{M A / C A}$ | PQVL/PVMH | $101.3 \pm 1.9$ | $21.6 \pm 0.1$ | $0.21 \pm 0.02$ |
| CA/NC | TKVL/VVQP | $31.6 \pm 5.9$ | $1.9 \pm 0.1$ | $0.06 \pm 0.01$ |

Table S3. Inhibition constants $\left(\mathrm{K}_{\mathrm{i}}\right)$ against HTLV-1 protease.

| Inhibitor | $K_{1}(\mu \mathrm{M})$ |
| :---: | :---: | :---: | :---: | :---: |
| Indinavir |  |
| (IDV) |  |
| Darunavir |  |
| (DRV) |  |

Table S4. X-ray data collection and crystallographic refinement statistics.

| Protease-Inhibitor | HTLV-DRV | HTLV-UM6 | HTLV-PU6 | HIV-PU6 |
| :---: | :---: | :---: | :---: | :---: |
| PDB ID | 6W6Q | 6W6R | 6W6S | 6W6T |
| Data Collection |  |  |  |  |
| Space group | $P 6{ }_{3} 22$ | $P 6{ }_{3} 22$ | $P 6{ }_{3} 22$ | $P 22_{1} 2_{1}$ |
| Cell dimensions: |  |  |  |  |
| $b$ ( $\AA$ ) | 78.5 | 77.9 | 76.6 | 58.0 |
| $c(\AA)$ | 160.6 | 160.1 | 157.3 | 61.7 |
| $\alpha, \beta, \gamma\left({ }^{\circ}\right)$ | 90, 90, 120 | 90, 90, 120 | 90, 90, 120 | 90, 90, 90 |
| Resolution ( $\AA$ ) | 40.1-2.10 | 41.9-2.05 | 39.3-2.29 | 21.9-1.84 |
| Resolution (A) | (2.18-2.10) | (2.12-2.05) | (2.37-2.29) | (1.91-1.84) |
| Unique reflections | 17823 (1728) | 18768 (1804) | 12954 (1244) | 16226 (1420) |
| Total reflections | 162887 (16621) | 173500 (15456) | 114508 (11155) | 104007 (4828) |
| $R_{\text {merge }{ }^{\text {a }}}$ | 0.09 (2.00) | 0.10 (3.49) | 0.24 (3.89) | 0.06 (0.29) |
| $R_{\text {pim }}$ | 0.03 (0.68) | 0.04 (1.25) | 0.09 (1.36) | - |
| CC1/2 | 1.00 (0.37) | 1.00 (0.23) | 0.99 (0.15) | - |
| CC* | 1.00 (0.73) | 1.00 (0.62) | 1.00 (0.50) | - |
| Completeness (\%) | 99.8 (100) | 99.8 (99.6) | 99.9 (99.9) | 98.4 (88.0) |
| Redundancy | 9.1 (9.6) | 9.2 (8.6) | 8.8 (9.0) | 6.4 (3.4) |
| Average I/ $\sigma$ | 12.6 (1.2) | 12.2 (0.7) | 5.9 (0.9) | 22.7 (3.3) |
| Wilson $B$-factors ( $\AA^{2}$ ) | 55.2 | 50.6 | 61.3 | 25.2 |
| Refinement |  |  |  |  |
| $R_{\text {factor (\%) }}{ }^{\text {c }}$ | 22.9 | 22.1 | 26.6 | 20.0 |
| $R_{\text {free }}(\%)^{\text {d }}$ | 26.2 | 24.3 | 30.5 | 22.7 |
| RMSD ${ }^{\text {b }}$ in: |  |  |  |  |
| Bond lengths ( $\AA$ ) | 0.007 | 0.012 | 0.006 | 0.003 |
| Bond angles ( ${ }^{\circ}$ ) | 0.81 | 1.32 | 0.82 | 0.59 |
| Ramachandran: 0.81 |  |  |  |  |
| Favored | 96.05 | 96.49 | 96.05 | 99.48 |
| Allowed | 3.95 | 3.07 | 3.95 | 0.52 |
| Outliers | 0.00 | 0.44 | 0.00 | 0.00 |

${ }^{\text {a }} R_{\text {sym }}=\Sigma|I-<I\rangle \mid / \Sigma I$, where $I=$ observed intensity, $\langle I\rangle=$ average intensity over symmetry equivalent; values in parentheses are for the highest resolution shell.
${ }^{\mathrm{b}}$ RMSD, root mean square deviation.
${ }^{c} R_{\text {factor }}=\Sigma \| F_{o}\left|-\left|F_{c}\right| / \Sigma\right| F_{o} \mid$.
${ }^{d} R_{\text {free }}$ was calculated from $5 \%$ of reflections, chosen randomly, which were omitted from the refinement process.

